<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615965</url>
  </required_header>
  <id_info>
    <org_study_id>2607/09</org_study_id>
    <nct_id>NCT01615965</nct_id>
  </id_info>
  <brief_title>Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer</brief_title>
  <official_title>Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to set up a model for detecting micrometastases in Lymph nodes
      of patients with prostate cancer by quantitative polymerase chain reaction and its impact on
      progression-free survival.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical recurrence free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Influence of molecularbiologic micrometastases in lymph nodes on biochemical recurrence free survival in comparison with patients who have histopathologic macrometastases or no evidence of lymph node metastases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of molecular detected lymph node micrometastases according to their topography</measure>
    <time_frame>2 years</time_frame>
    <description>Description of the anatomic distribution of molecularbiologic lymph node micrometastases in prostate cancer patients treated with radical prostatectomy and extended lymphadenectomy.
The frequency of molecular detected lymph node micrometastases according to their anatomic distribution at the obturatoric fossa, external iliac, internal iliac and common iliac arteries´ region will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>micrometastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tumor marker detection in lymph nodes</intervention_name>
    <description>tumor marker detection in lymph nodes by quantitative PCR</description>
    <arm_group_label>micrometastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate cancer

          -  Locally operable tumor

          -  Negative bone scan (obligatory if Gleason Score &gt; 7 or PSA &gt; 20ng/ml

          -  Karnofsky ≥ 80%

          -  Age 18 - 75 years

          -  Informed consent in written form

          -  Sufficient hematologic, coagulatory and renal function

          -  Compliant patient and geographic precondition for adequate follow-up given

        Exclusion Criteria:

          -  Manifest secondary tumor

          -  Organ metastases on CT-scan /MRI or in Histology

          -  Myocardial infarction or stroke within the last 6 months

          -  Severe cardiovascular (Grade III - IV according to NYHA), pulmonary (pO2 &lt; 60 mmHg),
             renal, hepatic oder hematopoetic impairment

          -  Severe active or chronic infection (z.B. pos. HIV-Antibody-Test, HBs-Ag-detected in
             Serum and/ or chronic Hepatitis)

          -  Severe psychiatric disease

          -  Previous chemotherapy

          -  Previous pelvine radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urologic Department</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.mriu.de</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>lymph node</keyword>
  <keyword>micrometastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Micrometastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

